SCHEMBL5386906

SCHEMBL5386906

CC(C)(C)OC(=O)NCc1ccc(NC(=S)NC(=O)c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
EPHX1 P07099 4/20 0.56
NAMPT P43490 2/20 0.55
MITF O75030 1/20 0.55
POLB P06746 1/20 0.55
LMNA P02545 3/20 0.55
HPGD P15428 1/20 0.55
MAPK1 P28482 1/20 0.55
HDAC1 Q13547 1/20 0.53
NPC1 O15118 3/20 0.53
NPSR1 Q6W5P4 3/20 0.53
RAB9A P51151 2/20 0.53
ALOX12 P18054 3/20 0.53
MEN1 O00255 1/20 0.53
RECQL P46063 1/20 0.53
KMT2A Q03164 1/20 0.53
MAPT P10636 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1258475 0.88 NAMPT (0.62) ALDH1A1NAMPTPOLBHPGDHDAC1
SCHEMBL16193025 0.85 NAMPT (0.60) ALDH1A1NAMPTPOLBHPGDHDAC1
SCHEMBL5383053 0.83 EPHX1 (0.68) ALDH1A1EPHX1MITFPOLBLMNA
SCHEMBL3975984 0.82 NAMPT (0.57) ALDH1A1NAMPTHPGDHDAC1NPSR1
SCHEMBL23899245 0.81 NAMPT (0.72) NAMPTLMNAHDAC1NPSR1MAPT
SCHEMBL3976512 0.81 NAMPT (0.56) ALDH1A1NAMPTPOLBLMNAHPGD
SCHEMBL5388847 0.80 NAMPT (0.58) NAMPTHDAC1NPSR1MAPT
SCHEMBL16192956 0.80 NAMPT (0.58) NAMPTPOLBHPGDMAPK1HDAC1
SCHEMBL24891652 0.80 NAMPT (0.66) NAMPTLMNAHDAC1NPSR1KMT2A
SCHEMBL6757735 0.79 SMN1; SMN2 (0.61) ALDH1A1EPHX1MITFLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7273880-B2 Selective NPY (Y5) antagonists H. LUNBECK A/S (DK) 2007-09-25 US disclosed
EP-1194421-B1 SELECTIVE NPY (Y5) ANTAGONISTS LUNDBECK & CO AS H (DK) 2005-10-12 EP disclosed
US-20050137240-A1 Selective NPY (Y5) antagonists H. LUNDBECK A/S (DK) 2005-06-23 US disclosed
EP-1194421-A4 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMA CORP (US) 2002-09-11 EP disclosed
EP-1194421-A1 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2002-04-10 EP disclosed
US-6225330-B1 Selective NPY (Y5) antagonists (tricyclics) SYNAPTIC PHARMACEUTICAL CORPORATION 2001-05-01 US disclosed
WO-2001002379-A1 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137240-A1 Selective NPY (Y5) antagonists NPY5R, NPY1R, NPY2R ALDH1A1 4658/4885EPHX1 3465/4885NAMPT 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.